Adding Zoledronate to Chemo, Surgery Not Effective for Osteosarcoma

Share this content:
Adding the bisphosphonate zoledronate to chemotherapy and surgery did not improve event-free survival in patients with osteosarcoma.
Adding the bisphosphonate zoledronate to chemotherapy and surgery did not improve event-free survival in patients with osteosarcoma.

Adding the bisphosphonate zoledronate to chemotherapy and surgery did not improve event-free survival in patients with osteosarcoma, a study published in The Lancet Oncology has shown.1

Because preclinical data demonstrated an antitumor effect with zoledronate in osteosarcoma, researchers evaluated whether zoledronate combined with chemotherapy and surgery improved event-free survival in pediatric and adult patients with osteosarcoma.

For this multicenter, open-label, phase 3 trial, investigators enrolled 318 patients aged 5 to 50 years with newly diagnosed high-grade osteosarcoma from 40 centers in France.

Adult patients older than 25 years were randomly assigned to receive doxorubicin, ifosfamide, and cisplatin with or without zoledronate 4 mg per infusion; patients aged less than 18 years received high-dose methotrexate-based chemotherapy with or without zoledronate 0.05 mg/kg per infusion; those aged 18 to 25 years were treated with either chemotherapy regimen at the discretion of the treating center, with or without zoledronate 0.05 mg/kg for the first 2 infusions, and 4 mg for the subsequent 8 infusions.

All patients received 10 infusions of zoledronate, 4 administered preoperatively and 6 given postoperatively.

At a median follow-up of 3.9 years, 3-year event-free survival was 63.4% (95% CI, 55.2-70.9) for patients who did not receive zoledronate, in contrast with 57.1% (95% CI, 48.8-65.0) for the zoledronate group (hazard ratio, 1.36; 95% CI, 0.95-1.96; P = .094). The study was stopped for futility.

RELATED: Variants in Pharmacokinetic Genes Linked to Ewing Sarcoma Outcomes

No major increase in any grade 3 or higher toxicity was observed with the addition of zoledronate, except for hypocalcemia and hypophosphatemia, both of which were expected. There was also no significant difference in orthopedic complications between the 2 groups.             

Reference

  1. Piperno-Neumann S, Le Deley MC, Redini F, Pacquement H, Marec-Bérard P, Petit P, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial [published online ahead of print June 17, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(16)30096-1.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs